Outcomes of Patients Undergoing Balloon Aortic Valvuloplasty in the TAVI Era: A Multicenter Registry

• Published in: The Journal of invasive cardiology Vol. 27; no. 12; pp. 547 - 553
• Main Authors: Moretti, Claudio, Chandran, Sujay, Vervueren, Paul-Louis, D'Ascenzo, Fabrizio, Barbanti, Marco, Weerackody, Roshan, Boccuzzi, Giacomo, Lee, Dae-Hyun, de la Torre Hernandez, Jose, Omedè, Pierluigi, Nijenhuis, Vincent, Igbineweka, Norris, Lim, Patrick, ten Berg, Carriè, Didier, Hildick-Smith, David, Gulino, Simona, Cannata, Stefano, Gargiulo, Giuseppe, Tamburino, Corrado, Conrotto, Federico, Meynet, Ilaria, Quadri, Giorgio, Marangoni, Ludovica, Taha, Salma, Biondi-Zoccai, Giuseppe, Salizzoni, Stefano, Marra, Sebastiano, Gaita, Fiorenzo
• Format: Journal Article
• Language: English
• Published: United States 01.12.2015
• Subjects: Aged, 80 and over; Aortic Valve Stenosis - therapy; Balloon Valvuloplasty - methods; Cardiac Catheterization - methods; Female; Follow-Up Studies; Heart Valve Prosthesis; Humans; Male; Registries; Retrospective Studies; Risk Factors; Time Factors; Transcatheter Aortic Valve Replacement - methods; Treatment Outcome
• ISSN: 1557-2501

Few clinical data about indications and prognoses of patients undergoing balloon aortic valvuloplasty (BAV) in the transcatheter aortic valve implantation (TAVI) era have been reported. Data from all consecutive patients undergoing BAV in seven European centers from 2006 to 2013 were collected. Acute results and long-term outcomes were assessed. A total of 811 patients aged 82 ± 9 years were included; 416 patients (51%) underwent BAV as palliative destination therapy, 320 patients (40%) as bridge to TAVI, and 75 patients (9%) as bridge to surgical aortic valve replacement (SAVR). Patients undergoing BAV as destination therapy had a higher risk profile (logistic EuroSCORE, 20 ± 17 vs 22 ± 14 vs 11 ± 8, respectively; P<.001). Post procedure, peak gradient decreased from 87 ± 22 mm Hg to 66 ± 22 mm Hg (P<.001) and aortic valve area increased from 0.61 ± 0.2 cm2 to 0.8 ± 0.2 cm2 (P<.001). At 30 days, the all-cause death rate (6.5% vs 6.2% vs 7.4%, respectively; P=.56) and the rate of life-threatening and major bleedings (8.0% vs 5.7% vs 6.0%, respectively) did not differ between groups. After a mean follow-up of 318 days (range, 116-500 days), rates of all-cause death were similar (30% vs 34% vs 31%, respectively; P>.99), although patients undergoing BAV as bridge to SAVR showed a lower cardiovascular death rate (11% vs 11% vs 3%, respectively; P=.04). In the TAVI era, BAV may represent a reasonable option for patients with severe aortic stenosis and temporary contraindications to definite therapy. Given the mortality rates at 30 days, patients should be carefully selected, while events at follow-up are deeply influenced by the decision of whether or not subsequent interventions are performed.